Affinity Asset Advisors, LLC Galectin Therapeutics Inc Transaction History
Affinity Asset Advisors, LLC
- $896 Million
- Q1 2025
A detailed history of Affinity Asset Advisors, LLC transactions in Galectin Therapeutics Inc stock. As of the latest transaction made, Affinity Asset Advisors, LLC holds 1,836,200 shares of GALT stock, worth $5.29 Million. This represents 0.25% of its overall portfolio holdings.
Number of Shares
1,836,200Holding current value
$5.29 Million% of portfolio
0.25%Shares
0 transactions
| Quarter | Operation | Price Per share | shares change | shares Held | SEC Form |
|---|
Others Institutions Holding GALT
# of Institutions
101Shares Held
9.89MCall Options Held
587KPut Options Held
2.02M-
Vanguard Group Inc Valley Forge, PA2.19MShares$6.31 Million0.0% of portfolio
-
Black Rock Inc. New York, NY1.56MShares$4.5 Million0.0% of portfolio
-
Advisor Group Holdings, Inc. Phoenix, AZ1.22MShares$3.52 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA853KShares$2.46 Million0.0% of portfolio
-
Geneos Wealth Management Inc.423KShares$1.22 Million0.02% of portfolio
About GALECTIN THERAPEUTICS INC
- Ticker GALT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 59,426,000
- Market Cap $171M
- Description
- Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. The company's lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, a galactoarabino-rhamnogalacturonan polysaccharide polymer that is in Phase III clinical trial f...